Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: A lesson learned from DeKAF Genomics

Transplant International

Volumn 26, Issue 10, 2013, Pages 982-989

  Israni, Ajay K ^a,b   Riad, Samy M ^a   Leduc, Robert ^b   Oetting, William S ^b   Guan, Weihua ^b   Schladt, David ^b   Matas, Arthur J ^a   Jacobson, Pamala A ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

acute rejection; kidney transplant; tacrolimus reduction; trough levels

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONFIDENCE INTERVAL; DRUG BLOOD LEVEL; FEMALE; FUNCTIONAL GENOMICS; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; TREATMENT DURATION;

ACUTE REJECTION; KIDNEY TRANSPLANT; TACROLIMUS REDUCTION; TROUGH LEVELS;

ADULT; AGE FACTORS; CALCINEURIN; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREAS TRANSPLANTATION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TACROLIMUS;

EID: 84884814193     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12155     Document Type: Article

References (29)

1. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, 2010: Figure KI 7.1.
2. Kidney Disease Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9: S14.
3. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS,. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977.
4. Spencer CM, Goa KL, Gillis JC,. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997; 54: 925.
5. Pallardo LM, Oppenheimer F, Guirado L, et al,. Calcineurin inhibitor reduction based on maintenance immunosuppression with mycophenolate mofetil in renal transplant patients: POP study. Transplant Proc 2007; 39: 2187.
6. Gaston RS, Cecka JM, Kasiske BL, et al,. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68.
7. Sellarés J, de Freitas DG, Mengel M, et al,. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388.
8. Kandaswamy R, Humar A, Casingal V, Gillingham KJ, Ibrahim H, Matas AJ,. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression. Transplantation 2007; 83: 722.
9. Matas AJ,. Chronic progressive calcineurin nephrotoxicity: an overstated concept. Am J Transplant 2011; 11: 687.
10. Matas AJ, Leduc R, Rush D, et al,. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study. Am J Transplant 2010; 10: 315.
11. Snanoudj R, Royal V, Elie C, et al,. Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am J Transplant 2011; 11: 2635.
12. Israni A, Leduc R, Holmes J, et al,. Single nucleotide polymorphisms, acute rejection and severity of tubulitis in kidney transplantation, accounting for center-to-center variation. Transplantation 2010; 90: 1401.
13. DA Laskow VF, Neylan JF, Mendez R, Matas AJ,. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 62: 900.
14. Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ,. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 61: 1576.
15. Kershner RP, Fitzsimmons WE,. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62: 920.
16. Mayer AD, Dmitrewski J, Squifflet JP, et al,. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436.
17. Golshayan D, Pascual M,. Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation. Transpl Immunol 2008; 20: 21.
18. Kidney Disease Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for the care of kidney transplant recipients: treatment of acute rejection. Am J Transplant 2009; 9: S21.
19. Naesens M, Lerut E, Damme BV, Vanrenterghem Y, Kuypers DRJ,. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. Am J Transplant 2007; 7: 2114.
20. Ciancio G, Burke G, Gaynor JJ, et al,. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008; 22: 200.
21. Filler G, Webb NJ, Milford DV, et al,. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion. Pediatr Transplant 2005; 9: 498.
22. Ciancio G, Burke GW, Gaynor JJ, et al,. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005; 80: 457.
23. Grenda R, Watson A, Vondrak K, et al,. A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. Am J Transplant 2006; 6: 1666.
24. Heilman RL, Chakkera H, Mazur M, et al,. Outcomes of simultaneous kidney-pancreas transplantation with positive cross-match. Transplant Proc 2009; 41: 303.
25. Gaston RS, Kaplan B, Shah T, et al,. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant 2009; 9: 1607.
26. Ekberg H, Tedesco-Silva H, Demirbas A, et al,. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
27. Ekberg H, Mamelok RD, Pearson TC, Vincenti F, Tedesco-Silva H, Daloze P,. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony Study. Transplantation 2009; 87: 1360.
28. Leichtman AB,. Balancing efficacy and toxicity in kidney-transplant immunosuppression. N Engl J Med 2007; 357: 2625.
29. Jacobson P, Oetting WS, Brearley AM, et al,.; for DeKAF investigators. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation 2011; 91: 300.